Controlled release technology for anti‐angiogenesis treatment of posterior eye diseases: Current status and challenges

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Advanced Drug Delivery Reviews

• Publication date

  2018-02-15

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1016/j.addr.2018.03.013PMID 29625138
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Stochastic Modeling of Degradation Behavior of Hydrogels

  2018cited by this paper
• Aflibercept Action in a Rabbit Model of Chronic Retinal Neovascularization: Reversible Inhibition of Pathologic Leakage With Dose-Dependent Duration.

  2018cited by this paper
• Novel brolucizumab fosters as real-world alternative for nAMD

  2017cited by this paper
• Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.

  2017cited by this paper
• In Vivo Efficacy of an Injectable Microsphere-Hydrogel Ocular Drug Delivery System

  2017cited by this paper
• Polymer degradation and drug delivery in PLGA-based drug-polymer applications: A review of experiments and theories.

  2017cited by this paper
• Hydrogel: Preparation, Characterization and Applications

  2017cited by this paper
• In vivo evaluation of hyaluronic acid based in situ hydrogel for prolonged release of Avastin in monkey

  2017cited by this paper
• Quantification of aflibercept and ranibizumab efficacy in DL-2-aminoadipic acid (DLAAA)-induced retinal neovascularization and vascular leakage in nonhuman primates

  2017cited by this paper
• Co-administration of an Antibody to Angiopoietin2 Extends the Duration of the Anti-Vascular Leak Activity of Aflibercept in a Model of Sustained Retinal Neovascularization (RNV)

  2017cited by this paper
• Pharmacokinetic aspects of retinal drug delivery.

  2017cited by this paper
• Engineered Hydrogels for Local and Sustained Delivery of RNA‐Interference Therapies

  2017cited by this paper
• Calcium phosphate nanoparticles-based systems for siRNA delivery

  2016cited by this paper
• Designing hydrogels for controlled drug delivery.

  2016cited by this paper
• Controlled and Extended In Vitro Release of Bioactive Anti-Vascular Endothelial Growth Factors from a Microsphere-Hydrogel Drug Delivery System

  2016cited by this paper
• Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept

  2016cited by this paper
• Virus-inspired nucleic acid delivery system: Linking virus and viral mimicry.

  2016cited by this paper
• Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates

  2016cited by this paper
• Efficient siRNA Delivery Using PEG-conjugated PAMAM Dendrimers Targeting Vascular Endothelial Growth Factor in a CoCl2-induced Neovascularization Model in Retinal Endothelial Cells.

  2016cited by this paper
• Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.

  2016cited by this paper
• Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model.

  2016cited by this paper
• PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.

  2016cited by this paper
• Single ocular injection of a sustained-release anti-VEGF delivers 6 months pharmacokinetics and efficacy in a primate laser CNV model

  2016cited by this paper
• Drug Delivery Engineering Principles For Drug Therapy

  2016cited by this paper
• Computational Modeling of Therapeutic Protein Distribution in the Rabbit Eye

  2016cited by this paper
• PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab.

  2016cited by this paper
• Chitosan Nanoparticles for SiRNA Delivery In Vitro.

  2016cited by this paper
• Formulation of in situ chemically cross-linked hydrogel depots for protein release: from the blob model perspective.

  2015cited by this paper
• Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics.

  2015cited by this paper
• A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab

  2015cited by this paper
• Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects.

  2015cited by this paper
• Profile of conbercept in the treatment of neovascular age-related macular degeneration

  2015cited by this paper
• Injectable Chemically Crosslinked Hydrogel for the Controlled Release of Bevacizumab in Vitreous: A 6-Month In Vivo Study.

  2015cited by this paper
• Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model

  2015cited by this paper
• Technologies for controlled, local delivery of siRNA.

  2015cited by this paper
• Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data.

  2015cited by this paper
• Implantable MicroPump for Drug Delivery in Patients with Diabetic Macular Edema.

  2014cited by this paper
• Computational modeling of drug delivery to the posterior eye

  2014cited by this paper
• Thiolated hyaluronan-based hydrogels crosslinked using oxidized glutathione: an injectable matrix designed for ophthalmic applications.

  2014cited by this paper
• Multi-arm PEG/silica hydrogel for sustained ocular drug delivery.

  2014cited by this paper
• Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study.

  2014cited by this paper
• Computational modeling of drug distribution in the posterior segment of the eye: effects of device variables and positions.

  2014influential reference
• Controlled release bevacizumab in thermoresponsive hydrogel found to inhibit angiogenesis

  2014cited by this paper
• Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study.

  2014cited by this paper
• Phosphorothioates, Essential Components of Therapeutic Oligonucleotides

  2014cited by this paper
• Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema.

  2014cited by this paper
• An Overview of Poly(lactic-co-glycolic) Acid (PLGA)-Based Biomaterials for Bone Tissue Engineering

  2014cited by this paper
• Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo.

  2014cited by this paper
• In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications.

  2014cited by this paper
• Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab

  2014cited by this paper
• Single compartment drug delivery.

  2014cited by this paper
• A NOVEL MODEL OF CHOROIDAL NEOVASCULARIZATION IN RABBITS

  2014cited by this paper
• Implants for drug delivery to the posterior segment of the eye: a focus on stimuli-responsive and tunable release systems.

  2014cited by this paper
• Animal models of age-related macular degeneration and their translatability into the clinic

  2014cited by this paper
• Hydrogel: Preparation, characterization, and applications: A review

  2013cited by this paper
• Hydrogel: Preparation, characterization, and applications

  2013cited by this paper
• Specific uptake of folate-decorated triamcinolone-encapsulating nanoparticles by retinal pigment epithelium cells enhances and prolongs antiangiogenic activity.

  2013cited by this paper
• Chapter II.4.3 - The Biodegradation of Biodegradable Polymeric Biomaterials

  2013cited by this paper
• Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration

  2013cited by this paper
• Ocular drug delivery systems: An overview.

  2013cited by this paper
• Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo.

  2013cited by this paper
• Accommodative movements of the vitreous membrane, choroid, and sclera in young and presbyopic human and nonhuman primate eyes.

  2013cited by this paper
• Liposomal drug delivery systems: from concept to clinical applications.

  2013cited by this paper
• Sustained release of Avastin® from polysaccharides cross-linked hydrogels for ocular drug delivery.

  2013cited by this paper
• Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes

  2013cited by this paper
• Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel.

  2012cited by this paper
• RNA-based therapeutics: current progress and future prospects.

  2012cited by this paper
• Animal models of age related macular degeneration.

  2012cited by this paper
• Hydrogels for protein delivery.

  2012cited by this paper
• Chitosan/siRNA nanoparticles encapsulated in PLGA nanofibers for siRNA delivery.

  2012cited by this paper
• One-step "click" method for generating vinyl sulfone groups on hydroxyl-containing water-soluble polymers.

  2012cited by this paper
• Strategies for ocular siRNA delivery: Potential and limitations of non-viral nanocarriers

  2012cited by this paper
• Intraocular pharmacokinetics of bevacizumab following a single intravitreal injection in humans

  2012cited by this paper
• Injectable polyplex hydrogel for localized and long-term delivery of siRNA.

  2012cited by this paper
• Retina-Choroid-Sclera Permeability for Ophthalmic Drugs in the Vitreous to Blood Direction: Quantitative Assessment

  2012cited by this paper
• Simulating Intravitreal Injections in Anatomically Accurate Models for Rabbit, Monkey, and Human Eyes

  2012cited by this paper
• Submacular DL-alpha-aminoadipic acid eradicates primate photoreceptors but does not affect luteal pigment or the retinal vasculature.

  2011cited by this paper
• INTRAOCULAR PHARMACOKINETICS AFTER A SINGLE INTRAVITREAL INJECTION OF 1.5 mg VERSUS 3.0 mg OF BEVACIZUMAB IN HUMANS

  2011cited by this paper
• Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier.

  2011cited by this paper
• Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.

  2011cited by this paper
• High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization.

  2011cited by this paper
• Controlled Release of Anti-inflammatory siRNA from Biodegradable Polymeric Microparticles Intended for Intra-articular Delivery to the Temporomandibular Joint

  2011cited by this paper
• Computer Modeling of Drug Distribution after Intravitreal Administration

  2011cited by this paper
• Determination of Injectable Intravitreous Volumes in Rats

  2011cited by this paper
• Modeling of drug release from bulk-degrading polymers.

  2011cited by this paper
• Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates.

  2011cited by this paper
• Computational modeling of drug transport in the posterior eye

  2010cited by this paper
• Comparison of Long-Acting Bevacizumab Formulations in the Treatment of Choroidal Neovascularization in a Rat Model

  2010cited by this paper
• Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.

  2010cited by this paper
• Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant.

  2010cited by this paper
• Subcellular targeting strategies for drug design and delivery

  2010cited by this paper
• Animal models of choroidal and retinal neovascularization.

  2010cited by this paper
• Simulating Dissolution of Intravitreal Triamcinolone Acetonide Suspensions in an Anatomically Accurate Rabbit Eye Model

  2010influential reference
• Protein delivery for retinal diseases: from basic considerations to clinical applications.

  2010cited by this paper
• Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

  2010cited by this paper
• Vitreous Volume of the Mouse Measured by Quantitative High-Resolution MRI

  2010cited by this paper
• RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027.

  2010cited by this paper
• THEORETICAL DESCRIPTION OF HYDROGEL SWELLING: A REVIEW

  2010cited by this paper
• Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration

  2010cited by this paper
• Ocular Drug Delivery

  2010cited by this paper

• Dual-functional hCe-pHEMA contact lenses for ocular antibiotic release, antioxidant protection, and in vivo corneal bacterial infection treatment.

  2025cites this paper
• Evaluation of the Duration of Good Visual Acuity During Anti-VEGF Therapy for Age-Related Macular Degeneration in Routine Clinical Practice

  2025cites this paper
• Next-generation smart ophthalmic biomaterials: From passive response to active interaction and closed-loop control

  2025cites this paper
• Nanomedicine-Based Ophthalmic Drug Delivery Systems for the Treatment of Ocular Diseases

  2025cites this paper
• Recent advances in engineered exosome-based therapies for ocular vascular disease

  2025cites this paper
• A review on revolutionizing ophthalmic therapy: Unveiling the potential of chitosan, hyaluronic acid, cellulose, cyclodextrin, and poloxamer in eye disease treatments.

  2024cites this paper
• Recent Progress in Polymeric Micelle-Enabled Targeted Nanotherapeutics for Diabetic Retinopathy

  2024cites this paper
• Latest Advances in Hydrogel Therapy for Ocular Diseases

  2024cites this paper
• Tacrolimus/hydroxypropyl-β-cyclodextrin-loaded nanoemulsions stabilized by Zein-Soluplus® nanoparticles for retinal diseases

  2023cites this paper
• Hopes and hurdles of nanogels in the treatment of ocular diseases

  2023cites this paper
• Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration

  2023cites this paper
• Nanofiber-coated implants: development and safety after intravitreal application in rabbits.

  2023cites this paper
• Fibroblast-Mimicking Nanodecoys for Multi-Target Antiangiogenesis in the Inflammation Treatment

  2022cites this paper
• Development of Anti-VEGF Prolonged Release Drug Delivery System Containing PLL Dendrimer and Hyaluronic Acid

  2022cites this paper
• Optimization of Lipid Nanoparticles by Response Surface Methodology to Improve the Ocular Delivery of Diosmin: Characterization and In-Vitro Anti-Inflammatory Assessment

  2022cites this paper
• Topical ophthalmic administration: Can a drug instilled onto the ocular surface exert an effect at the back of the eye?

  2022cites this paper
• Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies.

  2022cites this paper
• Hydrogels-based ophthalmic drug delivery systems for treatment of ocular diseases.

  2021cites this paper
• Recent trends in drug-delivery systems for the treatment of Diabetic Retinopathy and associated Fibrosis.

  2021cites this paper
• TAK1 signaling is a potential therapeutic target for pathological angiogenesis

  2021cites this paper
• NIR-triggered upconversion nanoparticles@thermo-sensitive liposome hybrid theranostic nanoplatform for controlled drug delivery

  2021cites this paper
• Back of the Eye Anatomy and Physiology: Impact on Product Development

  2021cites this paper
• Osthole: A Traditional Chinese Medicine for Ocular Anti-Angiogenic Therapy

  2020cites this paper
• PET study of ocular and blood pharmacokinetics of intravitreal bevacizumab and aflibercept in rats.

  2020cites this paper
• High-throughput synthesis, analysis, and optimization of injectable hydrogels for protein delivery.

  2020cites this paper
• Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration.

  2020cites this paper
• C-CBL is required for inhibition of angiogenesis through modulating JAK2/STAT3 activity in ROP development

  2020cites this paper
• Characterization, Stability, and In Vivo Efficacy Studies of Recombinant Human CNTF and Its Permeation into the Neural Retina in Ex Vivo Organotypic Retinal Explant Culture Models

  2020cites this paper
• Assessment of the safety of intravitreal injection of metoprolol tartrate in rabbits

  2020cites this paper
• Thermoresponsive gel for sustained release of BMP4 to inhibit corneal neovascularization.

  2020cites this paper
• Methylene Blue Prevents Retinal Damage Caused by Perinatal Asphyxia in the Rat

  2020cites this paper
• Local drug delivery systems for inflammatory diseases: Status quo, challenges, and opportunities.

  2020cites this paper
• Fasudil Loaded PLGA Microspheres as Potential Intravitreal Depot Formulation for Glaucoma Therapy

  2020cites this paper
• Topical Application of Hyaluronic Acid-RGD Peptide-Coated Gelatin/Epigallocatechin-3 Gallate (EGCG) Nanoparticles Inhibits Corneal Neovascularization via Inhibition of VEGF Production

  2020cites this paper
• Trimethyl chitosan-hyaluronic acid nano-polyplexes for intravitreal VEGFR-2 siRNA delivery: Formulation and in-vivo efficacy evaluation.

  2020cites this paper
• Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases

  2020cites this paper
• Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept

  2019cites this paper
• Long‐term therapeutic effect in nonhuman primate eye from a single injection of anti‐VEGF controlled release hydrogel

  2019influential citation
• role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept

  2019cites this paper
• role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept

  2019cites this paper
• Polysaccharides in Ocular Drug Delivery

  2019influential citation
• Intravitreal nanoparticles for retinal delivery.

  2019cites this paper
• Thermo-responsive polypeptides and micromechanical machines for sustained delivery to the posterior eye.

  2018cites this paper
• Pharmacokinetic Simulations of Intravitreal Biologicals: Aspects of Drug Delivery to the Posterior and Anterior Segments

  2018cites this paper